Latest News

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer

Company Commences Phase 2 Study at Multiple Academic Sites in United States Haddonfield NJ, October 13, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company [...]

Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer

Linnaeus announced today announced that it has entered into a clinical collaboration agreement with Merck to evaluate the combination of its lead investigational product candidate LNS8801, and Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab) in patients with [...]

Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti–PD-1/L1 Therapy

Linnaeus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or [...]

Load More Posts

We Listen to the Clinical Experience

We allow it to inform the science that drives the development of new treatments to treat cancer.

Contact Us